Case Report: An Unusual Course of Angiosarcoma After Lung Transplantation

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Jan 20

PMID 35046948

Authors

Saskia Bos

Liesbeth Daniels

Lucienne Michaux

Isabelle Vanden Bempt

Sascha Vermeer

F J Sherida H Woei-A-Jin

Patrick Schoffski

Birgit Weynand

Raf Sciot

Sabine Declercq

Laurens J Ceulemans

Laurent Godinas

Geert M Verleden

Dirk E Van Raemdonck

Lieven J Dupont

Robin Vos

Affiliations

Soon will be listed here.

Abstract

A 35-year-old woman underwent bilateral lung transplantation for primary ciliary dyskinesia and developed vascular tumors over a slow time course. Initial presentation of non-specific vascular tumors in the lungs and liver for up to 6 years after transplantation evolved toward bilateral ovarian angiosarcoma. Tumor analysis by haplotyping and human leukocyte antigen typing showed mixed donor chimerism, proving donor origin of the tumoral lesions. In retrospect, the donor became brain dead following neurosurgical complications for a previously biopsy-proven cerebral hemangioma, which is believed to have been a precursor lesion of the vascular malignancy in the recipient. Donor-transmitted tumors should always be suspected in solid organ transplant recipients in case of uncommon disease course or histology, and proper tissue-based diagnosis using sensitive techniques should be pursued.

References

Thoning J, Liu Y, Bistrup C, Thomassen A, Borst C, Marcussen N . Transmission of angiosarcomas from a common multiorgan donor to four transplant recipients. Am J Transplant. 2012; 13(1):167-73. DOI: 10.1111/j.1600-6143.2012.04301.x. View

Gandhi M, Strong D . Donor derived malignancy following transplantation: a review. Cell Tissue Bank. 2007; 8(4):267-86. DOI: 10.1007/s10561-007-9036-1. View

Kauffman H, McBride M, Cherikh W, Spain P, Marks W, Roza A . Transplant tumor registry: donor related malignancies. Transplantation. 2002; 74(3):358-62. DOI: 10.1097/00007890-200208150-00011. View

Nalesnik M, Woodle E, Dimaio J, Vasudev B, Teperman L, Covington S . Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant. 2011; 11(6):1140-7. DOI: 10.1111/j.1600-6143.2011.03565.x. View

Watson C, Roberts R, Wright K, Greenberg D, Rous B, Brown C . How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK Registry data. Am J Transplant. 2010; 10(6):1437-44. DOI: 10.1111/j.1600-6143.2010.03130.x. View

Zhang S, Yuan J, Li W, Ye Q . Organ transplantation from donors (cadaveric or living) with a history of malignancy: review of the literature. Transplant Rev (Orlando). 2014; 28(4):169-75. DOI: 10.1016/j.trre.2014.06.002. View

Bos S, Vos R, Van Raemdonck D, Verleden G . Survival in adult lung transplantation: where are we in 2020?. Curr Opin Organ Transplant. 2020; 25(3):268-273. DOI: 10.1097/MOT.0000000000000753. View

Wang Y, Chen J, Tang W, Zhang Y, Li X . Rapamycin inhibits the proliferation of endothelial cells in hemangioma by blocking the mTOR-FABP4 pathway. Biomed Pharmacother. 2016; 85:272-279. DOI: 10.1016/j.biopha.2016.11.021. View

Green M, Covington S, Taranto S, Wolfe C, Bell W, Biggins S . Donor-derived transmission events in 2013: a report of the Organ Procurement Transplant Network Ad Hoc Disease Transmission Advisory Committee. Transplantation. 2015; 99(2):282-7. DOI: 10.1097/TP.0000000000000584. View

10.

Ison M, Nalesnik M . An update on donor-derived disease transmission in organ transplantation. Am J Transplant. 2011; 11(6):1123-30. DOI: 10.1111/j.1600-6143.2011.03493.x. View

11.

Penn I . The incidence of malignancies in transplant recipients. Transplant Proc. 1975; 7(2):323-6. View

12.

Ison M, Hager J, Blumberg E, Burdick J, Carney K, Cutler J . Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant. 2009; 9(8):1929-35. DOI: 10.1111/j.1600-6143.2009.02700.x. View

13.

Desai R, Collett D, Watson C, Johnson P, Evans T, Neuberger J . Cancer transmission from organ donors-unavoidable but low risk. Transplantation. 2012; 94(12):1200-7. DOI: 10.1097/TP.0b013e318272df41. View

14.

McDermott J, Girgis R . Individualizing immunosuppression in lung transplantation. Glob Cardiol Sci Pract. 2018; 2018(1):5. PMC: 5857067. DOI: 10.21542/gcsp.2018.5. View

15.

Zheng N, Ding X, Jahan R . Low concentration of rapamycin inhibits hemangioma endothelial cell proliferation, migration, and vascular tumor formation in mice. Curr Ther Res Clin Exp. 2014; 76:99-103. PMC: 4229512. DOI: 10.1016/j.curtheres.2014.09.004. View

16.

Chambers D, Cherikh W, Harhay M, Hayes Jr D, Hsich E, Khush K . The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019; 38(10):1042-1055. PMC: 6816340. DOI: 10.1016/j.healun.2019.08.001. View

17.

Morath C, Schwenger V, Schmidt J, Zeier M . Transmission of malignancy with solid organ transplants. Transplantation. 2005; 80(1 Suppl):S164-6. DOI: 10.1097/01.tp.0000186911.54901.21. View

18.

Nadal M, Giraudeau B, Tavernier E, Jonville-Bera A, Lorette G, Maruani A . Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review. Acta Derm Venereol. 2015; 96(4):448-52. DOI: 10.2340/00015555-2300. View

19.

Van Raemdonck D, Vos R, Yserbyt J, Decaluwe H, De Leyn P, Verleden G . Lung cancer: a rare indication for, but frequent complication after lung transplantation. J Thorac Dis. 2016; 8(Suppl 11):S915-S924. PMC: 5124593. DOI: 10.21037/jtd.2016.11.05. View

20.

Desai R, Neuberger J . Donor transmitted and de novo cancer after liver transplantation. World J Gastroenterol. 2014; 20(20):6170-9. PMC: 4033455. DOI: 10.3748/wjg.v20.i20.6170. View